首页 学者频道 产业人才 学术频道 创新频道 全国学会 科协智库 人才评奖

LANTERN

南山 钟;Changzheng Wang;Xiangdong Zhou;Nuofu Zhang;Michael Humphries;Linda Wang;Chau Thach;Francesco Patalano;Donald Banerji

China Association for Science and Technology;Xinqiao Hospital;Third Military Medical University;Guangzhou Medical College;Beijing Novartis Pharma Co. Ltd.

发表时间:2015-6-5

期 刊:International Journal of COPD

语 言:English

U R L: http://www.scopus.com/inward/record.url?scp=84933526262&partnerID=8YFLogxK

摘要

Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators according to the patient’s airflow limitation, their history of exacerbations, and symptoms. The LANTERN study evaluated the effect of the long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator, QVA149 (indacaterol/glycopyrronium), as compared with the LABA/inhaled corticosteroid, salmeterol/fluticasone (SFC), in patients with moderate-to-severe COPD with a history of ≤1 exacerbation in the previous year. Methods: In this double-blind, double-dummy, parallel-group study, 744 patients with moderate-to-severe COPD with a history of ≤1 exacerbations in the previous year were randomized (1:1) to QVA149 110/50 µg once daily or SFC 50/500 µg twice daily for 26 weeks. The primary endpoint was noninferiority of QVA149 versus SFC for trough forced expiratory volume in 1 second (FEV1) at week 26. Results: Overall, 676 patients completed the study. The primary objective of noninferiority between QVA149 and SFC in trough FEV1 at week 26 was met. QVA149 demonstrated statistically significant superiority to SFC for trough FEV1 (treatment difference [∆]=75 mL; P<0.001). QVA149 demonstrated a statistically significant improvement in standardized area under the curve (AUC) from 0 hours to 4 hours for FEV1 (FEV1 AUC0–4h) at week 26 versus SFC (∆=122 mL; P<0.001). QVA149 and SFC had similar improvements in transition dyspnea index focal score, St George Respiratory Questionnaire total score, and rescue medication use. However, QVA149 significantly reduced the rate of moderate or severe exacerbations by 31% (P=0.048) over SFC. Overall, the incidence of adverse events was comparable between QVA149 (40.1%) and SFC (47.4%). The incidence of pneumonia was threefold lower with QVA149 (0.8%) versus SFC (2.7%). Conclusion: These findings support the use of the LABA/LAMA, QVA149 as an alternative treatment, over LABA/inhaled corticosteroid, in the management of moderate-to-severe COPD patients (GOLD B and GOLD D) with a history of ≤1 exacerbation in the previous year.

关键词

Clinical trial
COPD
Long-acting muscarinic antagonist
Long-acting β-agonists

相关科学

医学
健康策略
公共卫生、环境和职业健康
肺和呼吸医学

文献指纹

医学与生命科学

QVA149

Fluticasone-Salmeterol Drug Combination

Chronic Obstructive Pulmonary Disease

Forced Expiratory Volume

Muscarinic Antagonists

Bronchodilator Agents

indacaterol

Adrenal Cortex Hormones

Double-Blind Method

Incidence

Dyspnea

Area Under Curve

Pneumonia

Therapeutics

被引量

期刊度量

Scopus度量

年份 CiteScore SJR SNIP
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007 0.276 0
2008 0.264 0.187
2009 0.504 0.397
2010 0.594 0.638
2011 4.2 1.272 1.199
2012 4 1.145 0.805
2013 4.6 1.269 1.28
2014 5 1.293 1.328
2015 4.1 1.245 1.46
2016 3.7 1.257 1.101
2017 4.5 1.395 1.082
2018 4.7 1.424 1.187
2019 4.9 1.132 1.106
2020 5.2
2021

相似文献推荐